A1 Refereed original research article in a scientific journal
Novel Antiviral Activities of Obatoclax, Emetine, Niclosamide, Brequinar, and Homoharringtonine
Authors: Andersen P.I., Krpina K., Ianevski A., Shtaida N., Jo E., Yang J., Koit S., Tenson T., Hukkanen V., Anthonsen M.W., Bjoras M., Evander M., Windisch M.P., Zusinaite E., Kainov D.E.
Publisher: MDPI
Publication year: 2019
Journal: Viruses
Journal name in source: VIRUSES-BASEL
Journal acronym: VIRUSES-BASEL
Article number: ARTN 964
Volume: 11
Issue: 10
Number of pages: 15
DOI: https://doi.org/10.3390/v11100964
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/43810395
Viruses are the major causes of acute and chronic infectious diseases in the world. According to the World Health Organization, there is an urgent need for better control of viral diseases. Repurposing existing antiviral agents from one viral disease to another could play a pivotal role in this process. Here, we identified novel activities of obatoclax and emetine against herpes simplex virus type 2 (HSV-2), echovirus 1 (EV1), human metapneumovirus (HMPV) and Rift Valley fever virus (RVFV) in cell cultures. Moreover, we demonstrated novel activities of emetine against influenza A virus (FLUAV), niclosamide against HSV-2, brequinar against human immunodeficiency virus 1 (HIV-1), and homoharringtonine against EV1. Our findings may expand the spectrum of indications of these safe-in-man agents and reinforce the arsenal of available antiviral therapeutics pending the results of further in vitro and in vivo tests.
Downloadable publication This is an electronic reprint of the original article. |  |
